Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668950 · ClinicalTrials.gov registry record · Phase 3
Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT04668950 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 670 participants.
The verdict
NCT04668950, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. People around the United States and Canada can participate.
Interventions
- DRUG Placebo
- DRUG Fluvoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668950
The ClinicalTrials.gov registry entry for NCT04668950 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04668950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668950 about?
NCT04668950 is a clinical study titled "Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)". The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsi...
What is the current status of trial NCT04668950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2020-12-22. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT04668950?
The interventions under investigation include: Placebo (DRUG), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT04668950?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.